Breakthrough febrile neutropenia and associated complications in non-Hodgkin's lymphoma patients receiving pegfilgrastim

Acta Haematologica

Volumn 125, Issue 3, 2011, Pages 107-114

  Ng, Jia Hui ^a   Ang, Xiu Yun ^b   Tan, Sze Huey ^c,d   Tao, Miriam ^c   Lim, Soon Thye ^c   Chan, Alexandre ^b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Febrile neutropenia; Granulocyte colony stimulating factors; Lymphoma; Pegfilgrastim

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD CULTURE; BONE MARROW SUPPRESSION; CANCER REGISTRY; CANCER STAGING; COHORT ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FACTUAL DATABASE; FEBRILE NEUTROPENIA; FEMALE; HEPATITIS B; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 84984581079     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321545     Document Type: Article

References (15)

1. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2000; 34: 730-.751. (Pubitemid 34194843)
2. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: myeloid growth factors, v.1.2010. www.nccn . org/professionals/ physician-gls/PDF/ myeloid-growth.pdf
3. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC: 2006 update of recommendations for the use of white blood cell growth factors: an evidence- based clinical practice guideline. J Clin Oncol 2006; 24: 3187-.3205. (Pubitemid 46638957)
4. Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R, Paridaens R, Constenla M, Schwenkglenks M: Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 2009; 144: 677-.685.
5. Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, Dreiling L: Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 2007; 12: 484-.494. (Pubitemid 46698726)
6. Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E, Lazzarino M: Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006; 91: 496-.502.
7. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D: A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 37: 351-.360. (Pubitemid 30162545)
8. Lyman GH, Lyman CH, Agboola O: Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005; 10: 427-.437. (Pubitemid 40993570)
9. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004; 22: 4302-.4311. (Pubitemid 41185151)
10. Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M: Risk of febrile neutropenia among patients with intermediate- grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003; 44: 2069-.2076. (Pubitemid 37369646)
11. Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, Lawless G, Kerr R, Caggiano V, Delgado D, Fridman M, Ford J, Carter WB: The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate- grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001; 2: 47-.56. (Pubitemid 32677850)
12. Noga SJ, Choksi JK, Ding B, Dreiling L, Ozer H: Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study. Clin Lymphoma Myeloma 2007; 7: 413-.420. (Pubitemid 47061400)
13. Jenkins P, Freeman S: Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 2009; 20: 34-.40.
14. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M: Twoweekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-.641. (Pubitemid 38970554)
15. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: non-Hodgkin's lymphoma, v.1.2010. www. nccn.org/professionals/ physician-gls/PDF/ nhl.pdf